Patents by Inventor Toshifumi TATSUMI

Toshifumi TATSUMI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230241257
    Abstract: It is an object of the present invention to provide a novel halogenated biotin-modified dimer capable of performing imaging diagnosis or treatment. According to the present invention, a compound represented by the following formula (1) or a salt thereof is provided: wherein L1 represents a trivalent linking group, L2 represents a divalent linking group, Hal represents a halogen, p represents an integer of 1 to 5, and q, r, s, and t each independently represent an integer of 1 to 8.
    Type: Application
    Filed: April 13, 2021
    Publication date: August 3, 2023
    Applicants: THE UNIVERSITY OF TOKYO, SAVID THERAPEUTICS INC., FUKUSHIMA MEDICAL UNIVERSITY
    Inventors: Motomu KANAI, Kenzo YAMATSUGU, Toshifumi TATSUMI, Tatsuhiko KODAMA, Akira SUGIYAMA, Masanobu TSUKAGOSHI, Yuzo TODA, Kohshin WASHIYAMA, Kazuhiro TAKAHASHI, Songji ZHAO, Naoyuki UKON, Miho SUZUKI
  • Publication number: 20230149558
    Abstract: It is an object of the present invention to provide a conjugate of a duocarmycin derivative and a biotin-modified dimer, which is useful for pretargeting methods. According to the present invention, a compound represented by the following formula (1) or formula (2) is provided: wherein R1 and R2 each independently represent a hydrogen atom, a lower alkyl group, or a lower alkoxycarbonyl group; one of R3, R4, and R5 represents —O-L7-(Xaa)m-L6-N3, and the remaining two each independently represent a hydrogen atom, a lower alkyl group, or a lower alkoxycarbonyl group; X represents a reactive group; L6 and L7 each independently represent a divalent linking group; Xaa represents an amino acid residue; m represents an integer of 2 to 10; and Me represents a methyl group.
    Type: Application
    Filed: April 23, 2021
    Publication date: May 18, 2023
    Applicants: The University of Tokyo, SAVID THERAPEUTICS INC., TOHOKU UNIVERSITY
    Inventors: Motomu KANAI, Kenzo YAMATSUGU, Toshifumi TATSUMI, Tatsuhiko KODAMA, Akira SUGIYAMA, Masanobu TSUKAGOSHI, Hidetoshi TOKUYAMA, Juri SAKATA
  • Publication number: 20230125454
    Abstract: Objects of the present invention are to provide a novel phthalocyanine dye for use in photoimmunotherapy, and a method for producing the same, and to provide a conjugate of the above-described phthalocyanine dye and an antibody or a peptide. According to the present invention, a compound represented by the following formula (1) or a salt thereof is provided: wherein X represents a substituent having a hydrophilic group at the terminus thereof; L3, L4, L5, and L6 each independently represent a divalent linking group; Y represents a group capable of binding to an antibody or a peptide; R3 represents a substituent, such as an alkyl group containing 1 to 6 carbon atoms, an alkoxy group containing 1 to 6 carbon atoms, a halogen atom, —SR11, —SOR12, an aryl group containing 6 to 10 carbon atoms, —N(R13)(R14), or —NO2, wherein when a plurality of R3s are present, the plurality of R3s may be identical to or different from one another; and s represents an integer of 0 to 4.
    Type: Application
    Filed: February 4, 2021
    Publication date: April 27, 2023
    Applicants: THE UNIVERSITY OF TOKYO, SAVID THERAPEUTICS INC.
    Inventors: Motomu KANAI, Kenzo YAMATSUGU, Toshifumi TATSUMI, Kazuki TAKAHASHI, Tatsuhiko KODAMA, Akira SUGIYAMA, Masanobu TSUKAGOSHI, Yuzo TODA
  • Publication number: 20230106135
    Abstract: [Object] It is an object of the present invention to provide a conjugate of a biotin-modified dimer and a phthalocyanine dye, which is used in photoimmunotherapy. [Means for Solution] A compound represented by the following formula (1) or a salt thereof: wherein X represents a substituent having a hydrophilic group, a cationic group or an amino group at the terminus thereof, or —OH, and other groups have the meanings as defined in the description.
    Type: Application
    Filed: April 22, 2021
    Publication date: April 6, 2023
    Applicants: THE UNIVERSITY OF TOKYO, SAVID THERAPEUTICS INC.
    Inventors: Motomu KANAI, Kenzo YAMATSUGU, Toshifumi TATSUMI, Kazuki TAKAHASHI, Tatsuhiko KODAMA, Akira SUGIYAMA, Takefumi YAMASHITA, Masanobu TSUKAGOSHI, Yuzo TODA, Junji NISHIGAKI
  • Publication number: 20220348681
    Abstract: [Object] To provide a fusion protein of an antibody that recognizes cancer cells and a mutant streptavidin, which is for use in the treatment or diagnosis of cancer. [Means for Solution] A fusion protein comprising a protein-recognizing substance and the amino acid sequence as set forth in SEQ ID NO: 19 that is fused with the protein-recognizing substance.
    Type: Application
    Filed: April 22, 2021
    Publication date: November 3, 2022
    Applicants: THE UNIVERSITY OF TOKYO, SAVID THERAPEUTICS INC.
    Inventors: Toshiya TANAKA, Tatsuhiko KODAMA, Takefumi YAMASHITA, Motomu KANAI, Kenzo YAMATSUGU, Toshifumi TATSUMI, Takeshi KAWAMURA, Akira SUGIYAMA, Masanobu TSUKAGOSHI, Yuzo TODA, Junji NISHIGAKI
  • Publication number: 20220073641
    Abstract: It is an object of the present invention to provide a fusion protein of an antibody that recognizes cancer cells and a mutant streptavidin, which is for use in the treatment or diagnosis of cancer. According to the present invention, provided is a fusion protein having the amino acid sequence as set forth in SEQ ID NO: 2 or SEQ ID NO: 7, a linker sequence, and the amino acid sequence as set forth in SEQ ID NO: 1 (provided that the amino acid sequence portion consisting of 6 histidine residues at the C-terminus thereof may be partially or entirely deleted), from the N-terminal side to the C-terminal side, in this order.
    Type: Application
    Filed: December 27, 2019
    Publication date: March 10, 2022
    Applicants: The University of Tokyo, SAVID THERAPEUTICS INC.
    Inventors: Toshiya TANAKA, Tatsuhiko KODAMA, Takefumi YAMASHITA, Motomu KANAI, Kenzo YAMATSUGU, Toshifumi TATSUMI, Kazuki TAKAHASHI, Shumpei ISHIKAWA, Akira SUGIYAMA, Masanobu TSUKAGOSHI
  • Publication number: 20220016245
    Abstract: It is an object of the present invention to provide a conjugate of a biotin-modified dimer and a phthalocyanine dye, which is used in photoimmunotherapy. The present invention provides a conjugate of a compound represented by the following formula (1) or a salt thereof and a phthalocyanine dye: wherein the meaning of each of symbols is as defined in the specification.
    Type: Application
    Filed: August 8, 2019
    Publication date: January 20, 2022
    Applicants: The University of Tokyo, SAVID THERAPEUTICS INC.
    Inventors: Motomu KANAI, Kenzo YAMATSUGU, Toshifumi TATSUMI, Kazuki TAKAHASHI, Tatsuhiko KODAMA, Toshiya TANAKA, Takefumi YAMASHITA, Akira SUGIYAMA, Masanobu TSUKAGOSHI
  • Publication number: 20210214376
    Abstract: An object of the present invention is to provide a halogenated biotin-modified dimer, which is capable of imaging diagnosis or treatment by labeling with a halogen, a biotin-modified dimer having a high affinity for a mutant streptavidin with a low affinity for natural biotin. The present invention provides a compound represented by the following formula (1) or a salt thereof: wherein the meaning of each symbol is the same as that described in the specification.
    Type: Application
    Filed: May 30, 2019
    Publication date: July 15, 2021
    Applicants: THE UNIVERSITY OF TOKYO, SAVID THERAPEUTICS INC.
    Inventors: Motomu KANAI, Yohei SHIMIZU, Kenzo YAMATSUGU, Toshifumi TATSUMI, Tatsuhiko KODAMA, Akira SUGIYAMA, Masanobu TSUKAGOSHI